PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8487913

Necrotizing enterocolitis.

J H Jirka
View original source ↗Export metadata ↓

Abstract

In summary, NEC is the most common gastrointestinal emergency in the newborn. Premature infants are the most likely affected. Although progress has been made in elucidating some of the factors responsible for NEC, the exact etiology is still unclear. Aggressive medical management is required, but indications for surgical intervention differ from institution to institution. Overall mortality remains about 20% to 40%. About one half of survivors seem to have no sequelae, but the remaining infants may have significant ones which require additional surgical intervention or produce life long problems. Efforts at prevention have not been very successful. The single most important prophylactic measure would be to prevent prematurity. Until the exact pathogenesis of NEC is better understood, effective preventive measures are unlikely to be developed.

Explore related subjects

Enterocolitis, PseudomembranousHumansInfant, NewbornInfant, Premature, DiseasesPostoperative ComplicationsSurvival RateJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J H Jirka. 1993. Necrotizing enterocolitis.. https://pubmed.ncbi.nlm.nih.gov/8487913/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Pseudomembranous colitis: an update.

Clostridium difficile is the most common nosocomial infection of the gastrointestinal tract. Most cases are associated with antibiotic therapy that alters the fecal flora, allowing overgrowth of C difficile with production of its toxins. Diagnosis is made by detection of the organism or toxin in the stools. A variety of different tests can be used, but none is perfect. A stool culture can be positive in someone without diarrhea, ie, a carrier. While the cytotoxin is the gold standard, it is expensive, and there is a delay before results are available. Thus, many laboratories use the enzyme-linked immunoassay tests to detect toxin of C difficile because they are a more rapid screen. Depending on the specific test used, they can detect toxin A, toxin B or occasionally both. Sensitivity and specificity rates vary. First line therapy for C difficile disease should be metronidazole 250 mg qid for 10 days. Vancomycin should be reserved for severe cases where metronidazole has failed or where metronidazole cannot be tolerated or is contraindicated. Recurrent C difficile disease is a particularly vexing clinical problem. A variety of biotherapeutic approaches have been used. Retreatment with antibiotics is almost always necessary. In addition, the nonpathogenic yeast Saccharomyces boulardii has been showed to be of benefit as an adjunct in preventing further recurrences.

Enterocolitis, Pseudomembranous↗